Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Obesity

OPINION - The idea of using weight-loss drugs to get people back into work fills me with deep unease

There was a moment a couple of years ago, as weight-loss injections first erupted into popular consciousness, when it looked as though they couldn’t possibly endure. All right-thinking people were, it seemed, reflexively horrified by the suddenly rampant use and abuse of Ozempic and its compatriots by Hollywood elites. Disturbing…

Evening Standard

What are weight-loss jabs and how do they work?

Everything you need to know about ‘skinny jabs’.

The Independent UK

Unemployed to be given weight-loss jab to help them back into work

The new trial aims to gather evidence of the effects of the drug tirzepatide – sold by pharmaceutical company Lily under brand name Mounjaro

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug

Hims stock popped Monday after the FDA reportedly said it would reconsider its decision to bar compounders from selling knockoff tirzepatide.

Investors Business Daily

Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade

Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.

Investors Business Daily

New Zealand’s BMI threshold for publicly funded fertility treatment is outdated and unethical. Here’s why it should go

Women seeking publicly funded fertility treatment in New Zealand must have a body mass index (BMI) under 32, according to clinical priority assessment criteria for access to assisted reproductive technology.

The Conversation

Ultra-processed foods: we have the technology to turn them from foe into friend

Ultra-processed foods are the latest nutritional villains, associated with several diseases of the modern world, from obesity to heart disease. However, many nutritionists question whether the term “ultra-processed” does any more than create confusion. It only considers the way food is produced, ignoring other important factors like calories and nutrients.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Scientists find link between mental health at 11 and future obesity

Data from 4,556 11-year-olds and 3,791 14-year-olds considered overweight or obese was analysed

The Independent UK

Baby boomers living longer but are in worse health than previous generations

Obesity, type 2 diabetes, cancer, heart disease and other diseases all affecting people at younger ages, say experts

The Guardian - UK

Weight loss drugs shouldn’t create ‘dependency culture’, says Health Secretary

Mr Sweeting said it was in “everyone’s interest to play their part” and avoid overloading the health system.

Evening Standard

Obesity in the U.S. Is Finally Declining. You Can (Probably) Thank Ozempic.

The medication shouldn't be this controversial.

Reason

The US has passed peak obesity, a new survey suggests. Is it the Ozempic effect?

One in eight American adults have tried weight loss drugs

The Independent UK

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer

Viking Therapeutics stock is on the rise as the battle to develop new weight-loss drugs heats up. Here's what's at stake for the pharma giants fighting for position.

Investors Business Daily

Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.

Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

Ozempic’s cousin drug liraglutide is about to get cheaper. But how does it stack up?

Fourteen years ago, the older drug cousin of semaglutide (Ozempic and Wegovy) came onto the market. The drug, liraglutide, is sold under the brand names Victoza and Saxenda.

Barchart

This Weight-Loss Stock Just Scored a New Street-High Price Target

Down 43% from all-time highs, Structure Therapeutics is a pre-revenue clinical-stage biopharma company that trades at a massive discount to consensus price target estimates.

Dynamite News

Study shows how new type of blood test identify kids at risk of diabetes

Scientists have developed a novel blood test that uses lipids to identify children who are more susceptible to obesity such as type 2 diabetes, liver, and heart disease? Read further on Dynamite News:

Investors Business Daily

BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO

BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.

Get all your
news in one place.

100’s of premium titles.
One news app.

AAP

Pregnancy obesity increases risk of autism, ADHD

An analysis of more than 3.6 million mother-child pairs has found children born to obese mothers have double the risk of developing autism and ADHD.

Bored Panda

Fitness Influencer Banned From TikTok After Sparking Backlash For Harmful Dieting Advice

“What about all those influencers that promote obesity? Why aren’t their accounts being shut down?” The post Fitness Influencer Banned From TikTok After Sparking Backlash For Harmful Dieting Advice first appeared on Bored Panda.

Fortune

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

The Independent UK

Severe obesity is on the rise in the US

Obesity is high and holding steady in the U.S. About 4 in 10 Americans have obesity overall and about 1 in 10 have severe obesity

Roll Call

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

The Guardian - UK

Health and productivity losses from obesity ‘far outstrip weight-loss jab costs’

Exclusive: £100bn-a-year cost of obesity to UK makes clear economic case for use of drugs such as Ozempic, says report

Barchart

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

1 … 9 10 11 12

People

Lars Fruergaard Jørgensen

12 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.